Safety and efficacy of an rAd26 and r... - Lung Conditions C...

Lung Conditions Community Forum

55,519 members66,257 posts

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised control

2greys profile image
0 Replies

Between Sept 7 and Nov 24, 2020, 21 977 adults were randomly assigned to the vaccine group (n=16 501) or the placebo group (n=5476). 19 866 received two doses of vaccine or placebo and were included in the primary outcome analysis. From 21 days after the first dose of vaccine (the day of dose 2), 16 (0·1%) of 14 964 participants in the vaccine group and 62 (1·3%) of 4902 in the placebo group were confirmed to have COVID-19; vaccine efficacy was 91·6% (95% CI 85·6–95·2). Most reported adverse events were grade 1 (7485 [94·0%] of 7966 total events). 45 (0·3%) of 16 427 participants in the vaccine group and 23 (0·4%) of 5435 participants in the placebo group had serious adverse events; none were considered associated with vaccination, with confirmation from the independent data monitoring committee. Four deaths were reported during the study (three [<0·1%] of 16 427 participants in the vaccine group and one [<0·1%] of 5435 participants in the placebo group), none of which were considered related to the vaccine.

thelancet.com/journals/lanc...

Written by
2greys profile image
2greys
To view profiles and participate in discussions please or .
Read more about...

You may also like...

Covid 19 Vaccine side effects

I had my vaccine on Saturday morning during the night I woke with pain all over and breathing...

Investigational COVID-19 vaccine well-tolerated and generates immune response in older adults.

safety and efficacy....

pulmonary hypertension

asthma as originally diagnosed. Since joining this group I realised that it is not typical and as...

Sometimes the solution is simple !

doctor who confirms that low ferritin - low iron stores which can be treated with high doses of...